# Safety and Efficacy of Pembrolizumab in Combination With FLOT About Gastroesophageal Junction Cancer:

> **NCT06411171** · PHASE3 · NOT_YET_RECRUITING · sponsor: **xiaohua li** · enrollment: 36 (estimated)

## Conditions studied

- Gastroesophageal Junction Cancer

## Interventions

- **DRUG:** Pembrolizumab plus chemotherapy (FLOT)

## Key facts

- **NCT ID:** NCT06411171
- **Lead sponsor:** xiaohua li
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2024-06-01
- **Primary completion:** 2025-09-01
- **Final completion:** 2028-09-01
- **Target enrollment:** 36 (ESTIMATED)
- **Last updated:** 2024-05-17


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06411171

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06411171, "Safety and Efficacy of Pembrolizumab in Combination With FLOT About Gastroesophageal Junction Cancer:". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT06411171. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*